Additional information from baseline evaluations of patients with COPD recruited from randomised controlled trials of respiratory drugs also highlight the prevalence of nocturnal symptoms and sleep disturbance in COPD. Written By. We reviewed patients admitted for COPD exacerbation from May 2017 through July 2018 who were also screened for previously unrecognized and untreated OSA with a sleep questionnaire, and who subsequently underwent a high-resolution pulse oximetry or portable sleep monitoring study. Epidemiological reporting of sleep disturbance and night-time symptoms in COPD is limited. Hence, there is a pressing need for further research to establish the long-term health consequences of disturbed sleep in patients with COPD as a prelude to identifying appropriate measurement tools for use in interventional studies. This “forgotten” dimension warrants further clinical investigation with validated tools. 1,2 Complications such as heart disease or serious respiratory infections also become more likely as your lungs deteriorate. As in patients with OSA, sleep fragmentation in patients with overlap syndrome depends mainly on the sleep apnoea component, and it is thought to be responsible for their excessive daytime sleepiness. Conditions such as overlap syndrome – having both COPD and OSA – can seriously undermine health. In addition, NSF’s 2005 Sleep in America poll found that 26% of American adults are at high risk for OSA. If you have COPD and suspect that you may also suffer from OSA, talk to your physician about treatment options, including continuous positive airway pressure (CPAP). COPD and Sleep. If you aren’t getting an adequate amount of oxygen to your brain, you will feel restless, stressed or even confused at … Several studies have investigated the effects of bronchodilator therapy [19, 64–67]. Chronic obstructive pulmonary disease (COPD) affects millions of Americans and is the third leading cause of death in the United States. This proportion was lower (55.7%) among those with less well controlled asthma (ATAQ score 1–2; n = 923), particularly among those (6.9%) with very poorly controlled asthma (ATAQ score 3–4; n = 130). Further information can be found in our Privacy Policy. COPD and Death: What to Expect During End of Life Medically reviewed by Judith Marcin, M.D. No differences in lung function or overall survival were observed, but patients treated with noninvasive ventilation reported significantly better general health (SF-36 median score of 32 points with long-term oxygen therapy versus a median score of 20 with noninvasive ventilation; p = 0.0002) and mental health (median scores of 80 and 70, respectively; p = 0.009) [81]. Data are taken from [63]. However, the evaluation of night-time symptoms was not the primary outcome in any of these trials and, besides, the tools used to assess them had not been previously validated. These sleep disturbances may be related to multiple causes including demographic factors, such as age (most patients with COPD are over 50 yrs of age) and presence of obesity, pharmacotherapy, disease-specific symptoms, including wheezing and cough [33], or the presence of comorbid sleep disorders (e.g. Sleep in chronic obstructive pulmonary disease (COPD) is commonly associated with oxygen desaturation, which may exceed the degree of desaturation during maximum exercise, both subjectively and objectively impairing sleep quality. What is it? Despite improvements in survival by using acute non-invasive ventilation (NIV) to treat patients with exacerbations of COPD complicated by acute hypercapnic respiratory failure (AHRF), these patients are at high risk of readmission and further life-threatening events, including death. We thank T. Lonergan from Complete Medical Communications (Macclesfield, UK) who provided medical writing support funded by Almirall S.A., Barcelona, Spain. In order to explore appropriate management strategies to improved disturbed sleep in patients with COPD it may be necessary to operationally separate night-time symptoms related to the disease from sleep disturbance. Numerous dying patients want to know what to expect in the final stages of their illness. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. One exception is ramelteon, which was studied in mild and moderate COPD patients and found to not harm their breathing. Former NFL Star's Death Linked To Obstructive Sleep Apnea What happened to Reggie White? This is why you may have heard of things like people dying in their sleep without any signs of illness. The frequency of each variable was scored as follows: 0, never; 1, 1–2 times; 2, 3–4 times; 3, 5–6 times; and 4, ≥7 times. Although sleep disturbances may have a considerable negative impact on QoL in patients with COPD, it is important to keep in mind that relevant confounding factors have not been well established and are likely to be multiple. Among 470 subjects with current asthma from the Nordic European countries who took part in the European Community Respiratory Health Survey II, females were significantly more likely than males to report insomnia (p<0.0001) and excessive daytime sleepiness (p<0.0001), and female sex was a significant independent determinant for insomnia (adjusted OR 3.67, 95% CI 1.94–6.95) and excessive daytime sleepiness (adjusted OR 2.53, 95% CI 1.32–4.86). COPD is closely related to cigarette exposure in those who smoke or those who have secondhand exposure to smoke. Several validated tools are available. European Respiratory Society442 Glossop RoadSheffield S10 2PXUnited KingdomTel: +44 114 2672860Email: journals@ersnet.org, Print ISSN: 0905-9180 Causes of death in patients with COPD and chronic respiratory failure Monaldi Arch Chest Dis. Preparation for death – The lack of sleep as well as increased anxiety is known as the most common and troublesome COPD symptom associated with end of life. This blog post was written by Xavier Soler, MD, PhDChronic obstructive pulmonary disease (COPD) is very common leading to frequent physician visits and hospitalizations and become the 3rd leading cause of death in the U.S. COPD is the only major disease among the top 10 that continues to increase. At present there are no validated biomarkers that can inform accurately on whether an individual has fulfilled their sleep need or is in sleep deficit, so that there is no way to evaluate the clinical relevance of the reported sleep durations beyond the degree of deviation from an accepted population norm for healthy adults of 7–8 h per night. Introduction. Enter multiple addresses on separate lines or separate them with commas. Despite the apparent high prevalence of night-time symptoms and disturbed sleep in patients with COPD, there are only a few interventional studies that have directly targeted them. Reply. In fact, this study also identified a number of factors associated with reduced daily symptom variability (table 3), including maintenance treatment with a single long-acting bronchodilator (no versus yes; OR 2.062, 95% CI 1.358–3.132; p = 0.0007), treatment by a specialist versus a general practitioner (OR 1.390, 95% CI 1.082–1.785; p = 0.0099), and the severity of the breathlessness experienced by patients. Prevalence (per cent and 95% confidence interval) of night-time symptoms among patients with chronic obstructive pulmonary disease aged >40 yrs with a history of smoking, stratified by forced expiratory volume in 1 s (FEV1) % predicted. Reproduced from [77] with permission from the publisher. S. Rennard has served as a consultant or participated in advisory boards for: ABIM, Able Associates, Adelphi Research, Almirall, APT, Aradigm, Argenta, AstraZeneca, BI (ACCP), Biostrategies, BoomCom, Britnall and Nicolini, Capital Research, Chiesi, Clinical Advisors, CommonHealth, Complete Medical Group, Consult Complete, COPDForum, DataMonitor, Decision Resources, Defined Health, Dey, Dunn Group, Easton Associates, Enterprise Analysis, Equinox, Forest, Fulcrum, Gerson Lehman, GSK, Guidepoint, Hoffman LaRoche, IMS, Informed, Inspire, Insyght, KOL Connection, Leerink Swan, M. Pankove, MDRx Financial, MedaCorp, Medimmune, Mpex, Novartis, Nycomed, Oriel, Otsuka, Pearl, Pennside Partners, Pfizer, Pharma Ventures, Pharmaxis, Pick Research, Prescott, Price Waterhouse, Propagate, Pulmatrix, Pulmonary Reviews, Quadrant, Reckner Associates, Recruiting Resource, Reviews and Trends in COPD/Convergent Health Solutions, Roche, Sacoor, Schering, Schlesinger Medical, Scimed, Smith Research, Sudler and Hennessey, Talecris, Theravance, UBC and Uptake Medical, Vantage Point; has received lecture fees from AAAAI, Am Col Osteopathic Physicians, Asan Medical Center, ATS, AstraZeneca, California Soc Allergy, Convergent Health Solutions for Reviews and Trends in COPD, COPDFoundation, Creative Educational Concepts, Dey, Duke, France Foundation, Information TV, University of California-Los Angeles, Network for Continuing Education, Novartis, Nycomed, Otsuka, Pfizer, Sarasota Mem Hospital, Spanish Thoracic Society, University of Washington, University of Alabama-Birmingham, University of Pittsburgh, University of British Columbia, University of California-Davis and VA Sioux Falls; and has received industry sponsored grants from AstraZeneca, Biomarck, Centocor, GlaxoSmithKline, Mpex, Nabi, Novartis, Otsuka and Pfizer. 2) Current definitions of night-time symptoms in COPD span both respiratory and other symptoms of the disease itself, as well as symptoms of disturbed sleep such as frequent nocturnal awakenings, difficulty falling back to sleep after an awakening and shortened sleep duration. Chronic obstructive pulmonary disease (COPD) is expected to be the 3rd leading cause of death worldwide by 2020. COPD affects approximately 20 million people in the United States and is the nation’s third leading cause of death. She was 76 yrs young. and matching placebo on sleeping arterial oxygen saturation (Sa,O2) and sleep quality in 15 patients with moderate/severe stable COPD. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. 2177-2186, 10.1001/jama.2017.4451. Appropriate treatment strategies for patients with overlap syndrome are emerging. The authors found that 78.1% of patients reported some degree of night-time symptoms in relation to COPD, a much higher incidence than previous estimates of around 50% [31]. COPD is becoming increasingly common, but with diagnosis and treatment at Houston Pulmonary, Sleep & Allergy Associates in … [67] showed that treatment with salmeterol, a long-acting β2-adrenergic bronchodilator, improves arterial oxygen saturation during sleep without significant change in sleep quality. Obstructive sleep apnoea syndrome (OSAS) often coexists in patients with chronic obstructive pulmonary disease (COPD). ... “Patients with severe COPD commonly exhibit abnormal sleep like insomnia contributing to chronic fatigue, daytime sleepiness. Some lessons from these fields may be of interest for a better understanding of night-time symptoms in COPD patients. However, sleeping can also be dangerous. This may be achieved using validated scales to determine sleep duration and quality, the emergence of daytime symptoms or the impact upon health status or quality of life (QoL). Carbon monoxide poisoning from faulty ventilation and a poor heating source may contribute. Whether patients with COPD alone might have benefited further from CPAP therapy was not evaluated. Sleep quality is also relevant in terms of long-term health consequences [5]. Chronic obstructive pulmonary disease (COPD) is a common condition in primary care, rising from the fourth leading cause of death in the United States to the third. People with COPD rate their health worse than people without the condition. A lower arterial carbon dioxide tension (Pa,CO2), less oxygen usage per 24 h, and increased incidence of arrhythmias were seen in those patients who died suddenly. New technology may have the capacity to monitor cough during sleep in patients with COPD. When COPD is combined with OSA, the prevalence of cor pulmonale can be as high as 80%, according to one analysis, which also found that less than a third of COPD patients with cor pulmonale survive longer than five years. Good news: There are ways to improve the quality of your sleep. Several studies have documented that inflammation worsens in individuals who have nocturnal asthma during the night-time hours, as compared with those who have no nocturnal asthma of comparable asthma severity [94–97]. In this 12-week, randomised, double-blind, placebo-controlled study, 561 patients with COPD were treated with either aclidinium 200 μg or 400 μg, twice daily. We also use third-party cookies that help us analyze and understand how you use this website. Most investigators view the circadian cycles of cortisol, cholinergic tone, histamine and adrenaline as having theoretical relevance to inflammation, but the specific and detailed mechanistic links among these cycling biological processes and the control of inflammation remain incompletely defined [99]. Keep in mind that certain store-purchased and prescription sleep aids may impair breathing in COPD patients. COPD Myth 1: A COPD Diagnosis Is a Death Sentence “People live a long time with COPD,” Dr. Adams says. Sleep apnea and COPD. For example, Anzueto et al. The recall period was the previous month and patients were scored according to the number of days with sleep disturbances reported in that period. The present prospective cohort study tested the effect of OSAS treatment with continuous positive airway pressure (CPAP) on the survival of hypoxaemic COPD patients. In this study, among a population of 4,241 snorers referred to a sleep clinic between 1996 and 2000, 3,102 patients were diagnosed with OSA, of whom 598 were also diagnosed with COPD. These investigators conducted an internet survey of 803 patients with COPD in Europe and the USA. Sandra on May 23, 2016 at 11:37 pm . To address these issues, an expert panel meeting was convened on March 28, 2011 in Barcelona, Spain with the goal of discussing the aetiology, evolution, burden and management of night-time symptoms in COPD, as well as to explore current knowledge on how they impact long-term outcomes in these patients. [62] are of note. However, using the Profile of Mood States assessment, patients receiving noninvasive ventilation reported significantly more confusion and bewilderment (p = 0.020) and significantly less vigour (p = 0.050) [81]. In the Wisconsin Sleep Cohort follow-up published in Sleep in 2008, 42 percent of the deaths in people with severe sleep apnea were due to heart disease. By 2020, chronic obstructive pulmonary disease (COPD) is expected to be the 3rd leading cause of death in the world, especially in countries of middle to high income, like EU. This study, therefore, shows that the improvement in lung function obtained by the administration of aclidinium twice daily translates into symptomatic benefits to COPD patients, especially during sleep time and in the early morning [77]. COPD is the fourth leading cause of death in the United States, according to a report by the Centers for Disease Control and Prevention. Supplemental oxygen is commonly prescribed for COPD patient and has been shown to increase the quality and quantity of patients’ lives. In summary, night-time symptoms in COPD are prevalent, bothersome and likely to adversely impact long-term outcomes for patients, but they are often not reported and/or considered in the clinical management of the disease. In the study reported by McEvoy et al. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. While subjective sleep measures are informative, objective measures providing quantifiable data (e.g. People with COPD sometimes develop a barrel-shaped chest due to an enlargement of the lungs. Morning cough is often the earliest sign of the disease, followed by noisy breathing, chest pain, and breathlessness. This website uses cookies to improve your experience while you navigate through the website. In a recent study, 76% of patients reported frequent nocturnal awakening (table 1) [22–27]. COPD, or chronic obstructive pulmonary disease, is the fourth leading cause of death in the United States 3. COPD can also result in reduced blood oxygen levels, causing fatigue and leading to adverse health conditions. For people with COPD, symptoms such as coughing, chest pain, and frequent nighttime urination may profoundly impact sleep. The impact on sleep duration and quality can be recorded using validated tools such as the Pittsburgh Sleep Quality Index (PSQI) [48]. These cookies do not store any personal information. Sleep Tips for People With COPD . Many people who are diagnosed with COPD don’t sleep well because they have a harder time breathing at night. They found that, both mean Sa,O2 and the percentage of sleep spent below 90% of Sa,O2 improved significantly with salmeterol, whereas sleep quality was similar irrespective of salmeterol or placebo. Risk factor: Smoking. COPD is an incurable disease that can be fatal. Ventilation/perfusion mismatch resulting from progressive airflow limitation and emphysema is the key driver of this hypoxia, which may be exacerbated by sleep and exercise. End-stage COPD is marked by severe shortness of breath (dyspnea), even when at rest. In addition, medications used to treat COPD may cause insomnia or daytime sleepiness. CPAP reduces risk of death in people with COPD and sleep apnea EMBARGOED FOR RELEASE: 3 p.m. EDT, August 14, 2013 CONTACT: Lynn Celmer, 630-737-9700, ext. By clicking “Accept”, you consent to the use of ALL the cookies. Other non-disease-specific tools that are widely used and validated measures of HRQoL include the Euro-QoL-5D (EQ-5D) [56] and Short-Form 36 (SF-36) questionnaires. Therefore, the prevalence and clinical impact of sleep disturbances and night-time symptoms in COPD is not well understood and has not been a clinical focus to date. Unfortunately, COPD is often diagnosed once it has progressed from mild to severe and there is little opportunity for stopping or reversing its course. *: p<0.05; **: p<0.01; ***: p<0.001 versus placebo. Finally, it is well established that overnight oxygen therapy improves nocturnal oxygen saturation and pulmonary artery pressure during sleep [78, 79]. These inflammatory changes have been related to airflow limitation and reversibility [98]. The physical damage caused by COPD is irreversible, affecting either the airway or the air sacs in the lungs, known as alveoli 3. Each of them may need a specific method for assessment. 2) [63]. Now, the new study "shows that COPD is a risk indicator for sudden cardiac death in the general population, and that the risk increases with COPD severity," wrote … Although nocturnal respiratory symptoms, as well as symptomatic sleep disturbance, appear to be common in patients with COPD the term “night-time symptoms” has not been distinctly defined in an objective sense. Online ISSN: 1600-0617, Copyright © 2021 by the European Respiratory Society. This is a pre-requisite for the exploration and definition of the relationship between disturbed sleep and night-time symptoms in COPD. COPD, or chronic obstructive pulmonary disease is the fourth most common cause of deaths within the United States. We do not capture any email address. The most common end-of-life symptom of COPD is breathlessness -- a condition also referred to as dyspnea. QoL is widely used to determine the burden of disease and a wide variety of validated tools are available. In 2017–18, 1 in 5 (20%) of those aged 45 years and over with COPD rated their health as poor, compared with 5.4% of those aged 45 years and over without it. Cholinergic tone also has a normal circadian rhythm with higher levels during the sleeping hours, and this can lead to airflow limitation in patients with COPD [19]. More recently, a pan-European survey was undertaken to specifically explore the prevalence and impact of night-time symptoms in COPD patients [32]. In a randomised, double-blind, placebo-controlled, crossover study, these authors compared the effects of 4 weeks of treatment with salmeterol (50 mg b.i.d.) Symptoms of breathlessness can cause you to feel frequently out of breath or winded, and can occur in conjunction with cough. The PSQI has been validated in a variety of disease settings from primary insomnia to cancer [48, 49]. Whether this suppression of the cough reflex is also apparent in COPD patients is also unclear given that cough is reported by patients as one of the most troublesome nocturnal symptoms [63]. Publication of this peer-reviewed article was supported by Almirall SA, Spain (article sponsor, European Respiratory Review issue 121). Sleeping with COPD. Even COPD patients without obstructive sleep apnea (OSA) may experience a drop in oxygen during sleep. ***: p<0.001 versus all other times of day; ###: p<0.001 versus midday. Nocturnal symptoms of asthma negatively impact sleep quality as disease control declines [90]. Other nights, it would seem there was an actual buzz saw under…, Snoring can be a sore subject for bed partners, roommates, and family members. In summary, night-time symptoms in COPD warrant further clinical investigation with validated tools. COPD can affect your blood oxygen levels and your heart—and sleep apnea may make matters worse. In some cases, it is possible to alleviate symptoms by quitting smoking or avoiding environmental pollutants. Although both males and females have shown increases in their death rates each year, f… J. Hedner has received fees for speaking at research symposia by Weinmann GmbH and a fee for consulting with Almirall S.A. Thank you for your interest in spreading the word on European Respiratory Society . In fact, these are more common causes of death in people with COPD than the COPD itself. “Sleep apnea or sleep disordered breathing is a frequent comorbidity with COPD and should be treated to help avoid exacerbations,” says McCormack. Global Initiative for Chronic Obstructive Lung Disease, 2010, Behavioural and physiological consequences of sleep restriction, Sleep loss and sleepiness: current issues, Role of sleep duration in the regulation of glucose metabolism and appetite, The metabolic consequences of sleep deprivation, The association between sleep duration and weight gain in adults: a 6-year prospective study from the Quebec Family Study, A prospective study of sleep duration and mortality risk in women, Sleep and sleepiness in relation to stress and displaced work hours, Intra-individual variability in sleep duration and fragmentation: associations with stress, Actigraphic sleep duration and fragmentation are related to obesity in the elderly: the Rotterdam Study, Sleep in chronic obstructive pulmonary disease, Breathing around the clock: an overview of the circadian pattern of respiration, Endogenous circadian rhythm of pulmonary function in healthy humans, Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease, Ventilatory and waking responses to hypoxia in sleeping dogs, Regulation of respiration in sleeping dogs, Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases, The relation of sleep complaints to respiratory symptoms in a general population, Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep, Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease, Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease, Symptoms and experiences in chronic bronchitis and emphysema, Prevalence of sleep-related symptoms in a primary care population - their relation to asthma and COPD, Circadian-rhythm differences among emergency department patients with chronic obstructive pulmonary disease exacerbation, Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes, Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial, The prevalence and impact of nighttime symptoms in COPD patients – results from a cross-sectional study in five European countries, Proceedings of the IV World Asthma and COPD Forum (Paris, France, April 30 to May 3, 2011), Sleep and chronic obstructive pulmonary disease, Respiratory disorders during sleep in chronic obstructive pulmonary disease, Sleep-disordered breathing and COPD: the overlap syndrome, Breathing during sleep in patients with nocturnal desaturation, Contribution of hypoventilation to sleep oxygen desaturation in chronic obstructive pulmonary disease, Respiratory muscle activity during rapid eye movement (REM) sleep in patients with chronic obstructive pulmonary disease, Carbon dioxide responsiveness in COPD patients with and without chronic hypercapnia, Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease, Systemic effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep apnoea syndrome, Ventilatory, hemodynamic, sympathetic nervous system, and vascular reactivity changes after recurrent nocturnal sustained hypoxia in humans, Nocturnal hypoxemia and associated electrocardiographic changes in patients with chronic obstructive airways disease, Nocturnal deaths among patients with chronic bronchitis and emphysema, Implications of obstructive sleep apnoea for atrial fibrillation and sudden cardiac death, Day-night pattern of sudden death in obstructive sleep apnoea, Monitoring chronic cough: current and future techniques, Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia, Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients, A new method for measuring daytime sleepiness: the Epworth sleepiness scale, An instrument to measure functional status outcomes for disorders of excessive sleepiness, Further validation of the multidimensional fatigue symptom inventory-short form, Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale, Fatigue Impact Scale: its validation in patients with chronic obstructive pulmonary disease, Validation du questionnaire St Georges pour mesurer la qualité de vie chez les insuffisants respiratoires chroniques [Validation of the St George's questionnaire for measuring the quality of life in patients with chronic obstructive pulmonary disease], EQ-5D: a measure of health status from the EuroQol Group, Impaired sleep reduces quality of life in chronic obstructive pulmonary disease, Sleep quality predicts quality of life in chronic obstructive pulmonary disease, Factors affecting health status in COPD patients with co-morbid anxiety or depression, Development and psychometric assessment of the COPD and Asthma Sleep Impact Scale (CASIS), Development and first validation of the COPD Assessment Test, Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey, Symptom variability in patients with severe COPD: a pan-European cross-sectional study, Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD, Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease, Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD, Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease, Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease, Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD, Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease, Formoterol and tiotropium compared with tiotropium alone for treatment of COPD, Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial, Effect on lung function and morning activities of budesonide/formoterol, The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily, The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study, Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I, Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease, The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients, Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial, Sleep quality and quality of life in patients with hypertrophic cardiomyopathy, Prevalence and impact of nighttime symptoms in adults and children with asthma: a survey, Sleep in rheumatoid arthritis: a comparison with healthy subjects and studies of sleep/wake interactions, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease, Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnoea: the overlap syndrome, Impact of asthma control on sleep, attendance at work, normal activities, and disease burden, Asthma in men and women: treatment adherence, anxiety, and quality of sleep, Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study, Cytokines in bronchoalveolar lavage fluid of patients with nocturnal asthma, Relationship of plasma epinephrine and circulating eosinophils to nocturnal asthma, Circadian variation of sputum inflammatory cells in mild asthma, The relationship between sleep and asthma, Subglottic secretion drainage for preventing ventilator-associated pneumonia, Current and future applications of liquid biopsy in NSCLC, SLEEP AND CIRCADIAN RHYTHMS IN HUMAN BIOLOGY.